Genomic Study Presented at ASCO Explores Acquired Resistance to EGFR-targeted Lung Cancer Treatment | GenomeWeb

CHICAGO (GenomeWeb News) – An international team led by investigators from a company called the Cancer Therapeutic Innovation Group is using integrated genomics approaches to assess acquired resistance mechanisms in lung tumors treated with targeted therapy, attendees at the annual American Society of Clinical Oncology meeting heard here yesterday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.